By Doug Macron

Santaris Pharma last week responded to a patent-infringement suit filed by Isis Pharmaceuticals, denying the allegations and asking the court hearing the case to invalidate the gapmer-related intellectual property at issue.

In its countersuit, Santaris asked for a court declaration that it does not infringe, directly or indirectly, two Isis patents, as well as a ruling that both pieces of IP are “invalid and unenforceable.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.